This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): oxaliplatin for injection, Eloxatine, Elplat
Description: Eloxatin is a third generation platinum based drug. Eloxatin binds to DNA to prevent DNA replication. In tumor models, ELOXATIN, in combination with 5-FU, exhibits in vitro and in vivo antiproliferative activity greater than either compound alone.
Deal Structure: Eloxatin was developed in association with Debiopharm SA and is currently marketed by sanofi-aventis.
Yakult and Debiopharm
In 1997, Yakult Honsha acquired development and selling rights for Elplat in Japan from Debiopharm.
Debiopharm and Sanofi
In August 2002, Debiopharm and Sanofi renewed and extended the patent and know-how agreement on exolatin. The new agreement will expire in 2016.
Under the terms of this new agreement, Debiopharm and Sanofi will share development costs on improvements to the currently available formulations for Eloxatin, new indications and new methods of use for Eloxatin. Sanofi holds the marketing rights for Eloxatin worldwide, excluding Japan, Argentina, Paraguay, Uruguay and India. Sanofi pays royalties to Debiopharm on sales of Eloxatin.
Partners: Debiopharm S.A. Yakult Honsha Co. Ltd.
Pink Sheet Eloxatin FDA Reviewers
Pink Sheet Eloxatin Clinical Protocol
Pink Sheet Eloxatin Clinical Development
Additional information available to subscribers only: